Gilead's Sovaldi sales through the roof already, analyst predicts at least $8B this year
Hep C product on target to unseat Lipitor as the biggest-selling drug ever
March 7, 2014 | By Carly Helfand
With a revolutionary approach to hepatitis C and a price tag of $84,000 per 12-week treatment course, analysts expected big sales from Gilead's ($GILD) Sovaldi. Some even forecast it would reach $9 billion or more by 2017, at which level it would surpass Pfizer's ($PFE) Lipitor to take the crown for biggest-selling drug of all time. But none expected the exponential growth the drug is posting right now.
New Sovaldi prescriptions were up 20% week-over-week for the week ended Feb. 28--the 12th week of Gilead's launch. And according to ISI Group analyst Mark Schoenebaum, that has current projections looking rather slim.
"If prescriptions were to NEVER GROW AGAIN (i.e. flat-line from here), I estimate that 2014 sales will be $8B. If scrips grow an average of 1.5% week over week, I estimate that 2014 sales will be about $11B.
And as RBC analyst Michael Yee notes, Sovaldi's weekly total prescriptions are tracking 114% higher than
what Incivek--a Vertex ($VRTX) hep C drug that holds the title for fastest drug launch ever after raking in $1.56 billion in four quarters--did in its first full quarter of launch.
By: Martio Blanc
Investors Becoming Increasingly Bullish as Telsa Ramps up Sales in Europe & Asia Market
Analysts have estimated luxury car sales in China were around 1.4 million units last year, generating around $40 billion in revenues for automakers. Vehicle sales in the country are expected to double to almost three million units by 2020, and Tesla can tap into this growth to make serious inroads into the Chinese high-end car market.
used to do that to SRPT too, make it look like that is the high of the day. i wish people wouldn;t play games and just let this go up on it's own.
watch this take off next week now with exp. done, this is the next big e-commerce co.
Musk 5 Billion Gigafactory May Start Bidding Wars
“This would rank as the most attractive industrial project out there,” said Dennis Cuneo, president of DC
Strategic Advisors LLC and a former Toyota Motor Corp. executive who helped that carmaker select manufacturing sites.
Tesla has dubbed the project the “gigafactory,” and it would make Musk a force in both U.S. manufacturing and electric power. The plant he envisions would have more capacity than any other to make lithium-ion batteries.
This has a huge impact beyond Tesla,” said Harley Shaiken, a labor economist at the University of California, Berkeley. “It gives enormous legitimacy to battery production and the future of the electric car because that lies in the battery. It’s high stakes, high technology.”